CARB-X EXPANDS AWARDS TO AMICROBE BY $4.6M TO ACCELERATE DEVELOPMENT OF TWO DISTINCT AMICIDIN-Β TOPICAL ANTIMICROBIAL PRODUCTS

  23 June 2020

CARB-X announced today it is awarding US$4.6M to Amicrobe Inc. to expand development of its bioengineered Amicidin-β synthetic protein designed to kill bacteria and cleanse tissues. The new funding will help accelerate IND-enabling work on Amicidin-β Solution, which targets treatment of serious surgical and traumatic wound infections, and will also support prototyping of a new product for prevention of infection in low- and middle-income countries (LMIC).

Under the LMIC program, Amicrobe is designing and prototyping Amicidin-β/EF (extended formulation). This new formulation of Amicidin-β, perhaps as a foam, targets ease of use and climate-zone stability in parts of the world where cold storage systems are not always available for healthcare products. Rapid, effective tissue coverage is also a critical design goal.  Funding for the LMIC product is made possible by the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), a CARB-X partner that supports early-stage innovative research in underfunded areas of R&D to tackle antimicrobial resistance (AMR) for the benefit of people in LMICs.

Further reading: CARB-X
Author(s): Jennifer Robinson
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed